Home Blog Page 523

Gastops FluidSIGHT™ Awarded IDEaS Test Drives Contract Under Canada’s All Systems Go! Challenge

OTTAWA, ON, May 29, 2026 /PRNewswire/ — Gastops, a Canadian leader in intelligent condition monitoring and maintenance solutions, today announced it has been awarded a contract for FluidSIGHT™Â under Canada’s Innovation for Defence Excellence and Security (IDEaS) program as a Test Drives participant in the All Systems Go! challenge.

Gastops Ltd. Logo (CNW Group/Gastops Ltd.)
Gastops Ltd. Logo (CNW Group/Gastops Ltd.)

Test Drives enable the Department of National Defence (DND) and the Canadian Armed Forces (CAF) to evaluate innovative technologies in realistic operating environments to assess their potential to address future defence capability needs. As part of this effort, Gastops will further adapt and demonstrate its FluidSIGHT technology in support of advanced health and usage monitoring applications onboard military land vehicles, helping inform future capability decisions.

FluidSIGHT is a real-time oil condition, contamination, and wear monitoring system that provides continuous insight into the health of lubricated systems directly at the asset. FluidSIGHT allows operators to transition from periodic oil sampling to continuous, real-time condition awareness.

The IDEaS program has played a key role in advancing FluidSIGHT’s technical maturity. Through participation in an IDEaS Competitive Projects challenge, Gastops has progressed FluidSIGHT from an early proof‑of‑concept to a deployable, testable system suitable for evaluation. The Test Drives phase represents a critical step in validating the technology’s performance, integration readiness, and operational relevance alongside DND and CAF stakeholders.

“Being selected for IDEaS Test Drives reflects both the technical maturity of FluidSIGHT and its alignment with Canada’s defence innovation priorities,” said Shaun Horning, President and CEO at Gastops. “The IDEaS program has allowed us to systematically mature FluidSIGHT from concept to a product that can now be evaluated in a brand-new environment, military land vehicles, helping demonstrate how real-time oil condition awareness can improve equipment availability, safety, and maintenance decision‑making.”

Gastops brings decades of experience delivering diagnostics, prognostics, and condition‑based maintenance solutions for mission‑critical platforms across aerospace, defence, marine, energy, and industrial sectors. The IDEaS Test Drives project builds on this foundation and supports Canada’s objective to accelerate the adoption of innovative, Canadian-developed technologies in defence and security applications.

About Gastops

Gastops is the world’s leading provider of intelligent condition monitoring solutions used in Aerospace, Defence, Energy, and Industrial applications to optimize the availability, performance, and safety of critical assets. We offer peace of mind to our customers with innovative online monitoring sensors, at-line analysis, complex modeling and simulation, world-class laboratory testing, engineering, design, and MRO services that predict performance to enable proactive operating decisions. We have been providing powerful insights into the condition of critical equipment since 1979. Gastops is the intelligence inside what moves you.

www.gastops.com 

Media Contacts: media@gastops.com, +1 (613) 744-3530

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

  • Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b regimen of the ELEVATE study will be presented.
  • The efficacy data highlight how the combination of elacestrant and capivasertib has the potential to address key resistance mechanisms for patients with ER+/HER2- mBC, including ESR1 and PIK3CA co-existing mutations.
  • The company will also share updates on its elacestrant clinical development program, underscoring its potential in both mBC combination settings and as a monotherapy in early breast cancer.

FOR MEDICAL AND PHARMACEUTICAL TRADE MEDIA ONLY

FLORENCE, Italy and NEW YORK, May 29, 2026 /PRNewswire/ — The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present safety and preliminary efficacy for the elacestrant and capivasertib combination arm of the Phase 1b/2 ELEVATE study in patients with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC). Additionally, various other trial-in-progress updates will be presented, underscoring elacestrant’s potential as an endocrine therapy (ET) backbone across the spectrum of breast cancer. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.

The ELEVATE study was designed to evaluate the safety and efficacy of combination treatment options with elacestrant, to overcome different resistance mechanisms observed in ER+/HER2- mBC and improve patient outcomes, irrespective of ESR1 mutation status. The study is composed of six treatment regimens evaluating elacestrant in combination with CDK4/6 inhibitors (palbociclib, abemaciclib and ribociclib) and with inhibitors of the PI3K/AKT/mTOR pathway (everolimus, alpelisib and capivasertib).

ELEVATE results reported at ASCO 2026 (abstract 1098)[1] include safety and preliminary efficacy data from the phase 1b elacestrant (258-345 mg) plus capivasertib (320-400 mg) cohorts (n=31), which demonstrate preliminary median progression-free survival (mPFS) benefit in the recommended phase 2 dose (RP2D) cohort. The RP2D was determined in cohort 2 (n=9) to be elacestrant 345 mg plus capivasertib 320 mg BID (4 days on/3 days off).

In RP2D response-evaluable patients, preliminary efficacy showed an 88.9% disease control rate (DCR), a 66.7% clinical benefit rate at 24 weeks (CBR24), and a 33.3% objective response rate (ORR). All patients with ORR had co-existing ESR1 and PIK3CA mutations. The median duration of response (mDOR) has not yet been reached.  The preliminary mPFS was 11.3 months in the overall RP2D population, and 10.9 months in patients with co-existing ESR1 and PIK3CA mutations. Additionally, these initial results show that the combination is consistent with the known safety profiles of each targeted therapy plus standard of care endocrine therapy.

“The combination of elacestrant plus capivasertib is designed to address an unmet need for patients with ER+/HER2- PI3K-pathway altered metastatic breast cancer, particularly when co-existing ESR1 and PIK3CA mutations are present.” said Sara Tolaney, MD, MPH, Chief of the Division of Breast Oncology, Dana-Farber Cancer Institute.  “These encouraging preliminary data suggest the potential for extended clinical benefit with a manageable safety profile, as the combination regimen could simultaneously target ESR1 and PIK3CA mutations, potentially avoiding the need for sequential regimens that address each target individually.”

“Building on the data we saw last year at SABCS, we continue to be encouraged by elacestrant’s potential clinical benefit observed across numerous combinations with different agents targeting ER+/HER2- metastatic breast cancer,” said Elcin Barker Ergun, CEO of the Menarini Group. “The breadth of our studies, including early breast cancer and various combinations for ER+/HER2- metastatic breast cancer, including with capivasertib, demonstrate our commitment to bringing potentially transformational therapies to cancer patients.”

In addition, other elacestrant data will be presented at the ASCO congress. See below for a complete list of upcoming presentations:

Presentation Title: Elacestrant in combination with capivasertib in patients with ER+/HER2- advanced breast cancer: Update from ELEVATE, a phase 1b/2 open-label, umbrella study
Abstract Number: 1098
Presentation Date & Time: June 1, 2026; 1:30 – 4:30 PM CT
Location: Poster Board 212
Presenting Author: Wassim McHayleh

Presentation Title: ADELA: A double-blind, placebo-controlled, randomized phase 3 trial of elacestrant + everolimus versus elacestrant + placebo in ER+/HER2- advanced breast cancer patients with ESR1-mutated tumors progressing on endocrine therapy + CDK4/6i*#
Abstract Number: TPS1154
Presentation Date & Time: June 1, 2026; 1:30 – 4:30 PM CT
Location: Poster Board 262b
Presenting Author: Antonio Llombart-Cussac

Presentation Title: ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from ER+/HER2- breast cancer
Abstract Number: TPS1155
Presentation Date & Time: June 1, 2026; 1:30 – 4:30 PM CT
Location: Poster Board 263a
Presenting Author: Nuhad Ibrahim

Presentation Title: CAPELA: A phase II multicenter open-label randomized study of capecitabine in combination with elacestrant versus capecitabine alone in advanced estrogen receptor (ER)–positive breast cancer (TBCRC 070)*
Abstract Number: TPS1156
Presentation Date & Time: June 1, 2026; 1:30 – 4:30 PM CT
Location: Poster Board 263b
Presenting Author: Kristina Fanucci

Presentation Title: ELEGANT: Elacestrant versus standard endocrine therapy in women and men with node-positive, estrogen receptor-positive (ER+), HER2-negative (HER2-), early breast cancer with high risk of recurrence in a global, multicenter, randomized, open-label phase 3 study
Abstract Number: TPS1153
Presentation Date & Time: June 1, 2026; 1:30 – 4:30 PM CT
Location: Poster Board 262a
Presenting Author: Aditya Bardia

*Denotes investigator sponsored research or collaborative research

#The ADELA study is a pivotal study co-sponsored with MEDSIR

About The Elacestrant Clinical Development Program

Elacestrant is also being investigated in several company-sponsored clinical trials in metastatic breast cancer disease, alone or in combination with other therapies. ELEVATE (NCT05563220) is a phase 1b/2 clinical trial evaluating the safety and efficacy of elacestrant combined with alpelisib, everolimus, capivasertib, palbociclib, ribociclib or abemaciclib. ELECTRA (NCT05386108) is an open-label phase 1b/2, multicenter study evaluating elacestrant in combination with abemaciclib in patients with ER+, HER2- breast cancer. The phase 2 portion evaluates this treatment regimen in patients with brain metastases. ELCIN (NCT05596409) is a phase 2 trial evaluating the efficacy of elacestrant in patients with ER+, HER2- advanced/metastatic breast cancer who received one or two prior hormonal therapies and no prior CDK4/6 inhibitors in the metastatic setting. ADELA (NCT06382948) is a phase 3 randomized, double-blinded trial evaluating elacestrant in combination with everolimus in patients with ER+, HER2- mBC with ESR1-mut tumors. ELEGANT (NCT06492616) is a phase 3 trial evaluating the effectiveness of elacestrant versus standard endocrine therapy in women and men with node-positive, ER+, HER2- early breast cancer with high risk of recurrence. Elacestrant is also being evaluated in additional investigator-led trials, in trials conducted in collaboration with other companies, in metastatic breast cancer as well as in early disease.

To report SUSPECTED ADVERSE REACTIONS, contact Stemline Therapeutics, Inc. at adverseevents@menarinistemline.com. All of the relevant information can be found at https://stemline.com/contact/

Full prescribing information for elacestrant can be found at https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu#product-info

About The Menarini Group

The Menarini Group is a leading international pharmaceutical and diagnostics company, with a turnover of $5.5 billion and over 17,000 employees. Menarini is focused on therapeutic areas with high unmet needs with products for cardiology, oncology, pneumology, gastroenterology, infectious diseases, diabetology, inflammation, and analgesia. With 18 production sites and 9 Research and Development centers, Menarini’s products are available in 140 countries worldwide. For further information, please visit www.menarini.com.

About Stemline Therapeutics Inc.
Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on bringing transformational oncology treatments to patients. Stemline commercializes elacestrant, an oral endocrine therapy indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy, in the U.S., Europe, and other global regions. Stemline also commercializes tagraxofusp-erzs, a novel targeted therapy directed to CD123, for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic cancer, in the United States, Europe, and other global regions. In addition, Stemline commercializes selinexor, an XPO1 inhibitor for multiple myeloma, in Europe. The company is also conducting multiple label-expansion studies with elacestrant and tagraxofusp in breast and hematologic cancer indications, respectively, and has an extensive clinical pipeline of additional drug candidates in various stages of development for a host of solid and hematologic cancers.

[1] The safety and efficacy of the investigational combinations and unapproved indications discussed in this press release have not been established by the FDA, EMA, or any other regulatory authority.

 

Atlantis Sanya Readies for Summer Tourism Market

Multi-Dimensional Upgrades Elevate Premium Family Vacations

SANYA, China, May 29, 2026 /PRNewswire/ — As the 2026 summer travel season approaches, Atlantis Sanya is unveiling a series of upgrades designed to elevate premium family vacations and enrich Hainan’s summer tourism market. The resort is expanding its offerings across family entertainment, marine education, nightlife experiences, dining, and wellness, reflecting the growing demand for diverse and immersive travel experiences. Among the highlights are the highly popular 20th Anniversary Octonauts Family Ocean View Rooms, featuring immersive interiors and exclusive animations, alongside a newly upgraded Octonauts Kids Club with seven themed zones and more than 40 interactive activities combining entertainment and marine learning.


The resort has also enhanced its signature “One Ticket, Two Venues, Three Performances” aquarium experience, allowing guests to explore The Lost Chambers Aquarium, Dolphin Cay, and enjoy popular marine-themed performances. Further strengthening its marine conservation initiatives, Atlantis Sanya recently opened the Sea Turtle Shelter, a new ecological conservation facility focused on sea turtle rescue, rehabilitation, breeding, and educational study tours, supported by an international conservation team.

For summer entertainment, the Aquaventure Waterpark Music Festival will return with extended operating hours and a transformed 7,000-square-metre wave pool featuring an innovative “wave pool karaoke” experience. Meanwhile, the resort’s resident production, C Show, will debut refreshed choreography and upgraded stage effects, delivering an immersive performance that combines land, water, and aerial elements. On the culinary front, Saffron Buffet Restaurant will launch an all-you-can-eat seafood and durian festival, featuring fresh seafood and over 100 Chinese and Western dishes.

On the wellness and healthcare front, Atlantis Sanya has partnered with Sanya Traditional Chinese Medicine Hospital to launch a Traditional Chinese Medicine (TCM) wellness centre, offering a range of therapies such as acupuncture, moxibustion, tuina massage, and customised herbal treatments. The resort has also entered into a strategic partnership with the Peking University School and Hospital of Stomatology, Sanya Branch, providing guests with access to premier oral and dental healthcare services while they stay with Atlantis Sanya. Together, these initiatives form a comprehensive “tourism + wellness + medical care” model, designed to meet the rising demand for high-quality health-and-wellness travel experiences while supporting the sustainable growth of Hainan’s cultural tourism industry.

Nu Stadium, Miami Freedom Park and Boldyn Networks deliver 360° connectivity experience at Inter Miami CF’s new home

Converged network elevates fan experiences and operational efficiencies

NEW YORK, May 28, 2026 /PRNewswire/ — Boldyn Networks (Boldyn), an Official Supplier of Major League Soccer (MLS) and a global leader in shared network infrastructure, successfully deployed a comprehensive connectivity and advanced technology platform at Nu Stadium in Miami Freedom Park ahead of the stadium’s April debut. The 26,700-seat stadium -set within a sprawling 131-acre mixed-use development- serves as the permanent home of Inter Miami CF, the reigning 2025 MLS Cup Champions. The newly activated network supports high-performance connectivity for fans, venue operations, and next generation digital experiences from day one.

Experts panel at Tech Week
Experts panel at Tech Week

A Converged Network for a Future-Ready Stadium

As Boldyn continues to deliver on its MLS-wide promise to transform game day connectivity, this latest deployment reflects a powerful milestone: a fully integrated and future-ready converged platform. This includes high-density Wi-Fi 7, IPTV, audio and neutral host cellular connectivity (DAS), and a converged fiber plant meeting all broadcast, cellular and IT needs within the same infrastructure.

Transparent and Predictable Financial Model

All elements were delivered through an innovative Technology as a Service model, eliminating the need for significant upfront capital investment by the club. Boldyn invested the necessary capital to deploy a fully modern technology stack, enabling immediate access to advanced capabilities. Nu Stadium benefits from state-of-the-art technology from day one-paired with the long-term commitment of Boldyn as a collaborator to operate and manage the network. This approach ensures sustained performance, scalability and continuous innovation over time.

Nu Stadium and Miami Freedom Park represent the latest addition to Boldyn’s growing portfolio, demonstrating how advanced technology and creative financing models can come together to elevate the fan experience.

A digital-first stadium for a digital-first fan base 
Fans experience lightning-fast connections, seamless digital experiences, and a stadium that functions as part of a larger connected campus. Boldyn’s converged fiber-based architecture supports all mission-critical stadium systems and enhances day-to-day operations, including:

  • Always-on connectivity: More than 600 access points for high-density Wi-Fi and cellular support to connect fans and staff throughout the stadium and across the 131-acre development.
  • Immersive fan experiences: The network enables frictionless mobile ticketing, in-seat ordering, and interactive content. Content innovators have also integrated immersive AR/VR experiences to transform how fans interact with the match.
  • Operational excellence: A converged system manages thousands of networked devices, including building management, lighting, security cameras, and audio speakers to ensure the venue runs at peak efficiency.
  • Data and insights: Cloud-based IoT platforms and custom dashboards deliver real-time analytics on crowd management and fan behavior, allowing stadium operators to improve safety and staff coordination.
  • Broadcasting and media: The infrastructure includes extensive cabling to support streaming game broadcasts and over 200 connected TVs so fans never miss a moment of the action.

Jason Caliento, CCO US, Boldyn Networks said: “When we announced our MLS partnership last year, we made a promise to elevate the league’s digital experience. Our work with the incredible team at Miami Freedom Park is proof we’re delivering. We’re designing, building and operating the entire tech stack in Miami with an innovative financial structure, and we’re expanding partnerships with best-in-breed providers AmpThink and MasTec. With this model, we’re able to deliver state-of-the-art experiences for Inter Miami fans and provide ownership with significant financial flexibility. We’re confident it’s a model that teams around the country will want to emulate.”

Chris Schlosser, Senior Vice President Emerging Ventures, MLS commented: “In 2025 the MLS once again had the second highest attendance in global soccer, and our live fan experience continues to be an area of focus across the league. Inter Miami and Miami Freedom Park’s work with Boldyn Networks demonstrates an outstanding commitment to a state-of-the-art fan experience and serves as a testament to the innovative advancements we’re making as a league.”

Delivering on the MLS Vision to Elevate the Fan Experience

Boldyn continues to scale its league-wide impact. As an Official Supplier of MLS, the company is designing and deploying seamless, secure, and scalable connectivity across matchday venues, training grounds, and fan experiences.

Nu Stadium and Miami Freedom Park mark a new chapter where technology, creativity, and community come together to deliver a global-caliber venue in the heart of Miami.

About Boldyn Networks

Boldyn Networks designs, builds, and operates advanced network infrastructure where connectivity matters most. As the world’s leading neutral host provider, we enable mobile operators, large enterprises, and government agencies to create exceptional connected experiences no matter how complex the environment. From major transport systems, airports, stadiums, campuses and military bases to industrial hubs and smart cities, Boldyn brings 5G, fiber, Wi‑Fi, private 5G networks, and IoT together into tailored resilient, high‑performance platforms.

Learn more at: www.boldyn.com

Hong Kong rises to world No.1 cross-boundary wealth hub


HONG KONG SAR – Media OutReach Newswire – 28 May 2026 – Hong Kong has overtaken Switzerland as the world’s top cross-boundary wealth management centre, according to the latest Global Wealth Report 2026 published by the Boston Consulting Group (May 27).

Hong Kong has emerged as the world's largest cross-boundary wealth management centre
Hong Kong has emerged as the world’s largest cross-boundary wealth management centre

Hong Kong’s cross-boundary wealth rose 10.7% in 2025 to US$2.9 trillion, driven by Chinese Mainland flows and a vigorous stock market that delivered significant IPO (initial public offering) activity and strong gains in benchmark-heavy internet platforms, according to the report. It also projected that, from 2025 to 2030 the cross-boundary wealth managed by Hong Kong will grow by 9% on average annually and maintain first place globally, fully affirming Hong Kong’s position as a world-leading cross-boundary wealth management centre.

Paul Chan, Financial Secretary of the Hong Kong Special Administrative Region Government (HKSARG), highlighted that China’s National 15th Five-Year Plan clearly supports Hong Kong in strengthening its functions as an international asset and wealth management centre, which is also a key component of Hong Kong’s ‘Finance +’ development strategy.

“Over the past few years, the Government has worked closely with the financial sector to continuously improve the financial infrastructure and ecosystem, expand the range of investment products and risk management tools, and deepen the connectivity with capital markets around the world.

“Leveraging the advantages of ‘one country, two systems’, complemented by free, open, transparent, and predictable economic policies as well as a stable and secure investment environment, and cross-market connectivity, Hong Kong is attracting more and more ultra-high-net-worth individuals and family offices to establish a presence and invest in the city,” Mr Chan said.

Hong Kong rises to world's top cross-boundary wealth management centre (1).jpg

Christopher Hui, Secretary for Financial Services and the Treasury of the HKSARG, noted that the Government had issued the Policy Statement on Developing Family Office Businesses in Hong Kong in March 2023 and has since implemented various measures to encourage family offices to operate in Hong Kong. Such initiatives, he said, include providing profits tax concession to family-owned investment holding vehicles managed by eligible single family offices and introducing the New Capital Investment Entrant Scheme.

“The Government will introduce legislative proposals into the Legislative Council next month (June 2026) to further enhance the preferential tax regimes for funds, single family offices and carried interest, so as to further enhance the competitiveness of the tax regimes, and attract more funds and family offices to set up and operate in Hong Kong,” Mr Hui said.

According to a study commissioned by Invest Hong Kong and published in February 2026, there were over 3,380 single family offices operating in Hong Kong as of end-2025, representing an increase of more than 25%, over the past two years.

Hashtag: #HongKong #BrandHongKong #Global #Wealth #Management #Top





The issuer is solely responsible for the content of this announcement.

Global Filmmakers Are Leveraging Kling AI to Push the Boundaries of Storytelling, Cannes Panel Presents


CANNES, FRANCE – Media OutReach Newswire – 28 May 2026 – A shift is underway in the global film industry as creators across the globe embrace Kling AI to produce cinematic-level visuals and push the boundaries of storytelling.

Native 4K Generation for Cinematic-Level Output

“For House of David, we did it for a third of what the studios told us we needed,” said Jon Erwin, the writer and producer of House of David, founder and Chief Creative Officer of Wonder Project.

For House of David, Kling AI has served as its core foundation model and benchmark tool. Across both season one and two, Kling AI has generated the vast majority of its production shots, leading the share of its AI workflows for the show. While Season One of House of David incorporated 72 shots invovling the use of AI, its second season used more than four times as many AI shots compared to the first season.

Emotional Expressiveness for Feature Film

Raphael, South Korea’s first full-length feature created entirely using generative AI, is a large-scale production being developed by Mateo AI Studio. Currently in production with the goal of a theatrical release in 2026, this project is leveraging Kling AI’s powerful video model throughout the production process to maximize distinctive visual effects and deliver a differentiated cinematic experience.

Realism and Visual Quality for Theatrical Screens

Born of the Tide, the first AI-generated cinematic epic exploring China’s Tanka community, often referred to as “sea nomads” for their long-standing floating way of life, leverages Kling AI’s 4K capabilities to present its sweeping, high-stakes spectacles, such as massive dragon boat races, explosive fish market bombings, and sprawling mountain battles.

“Kling AI faithfully preserves the director’s intended color tones without losing stylistic consistency during the video generation process. The platform also delivers rare realism in rendering waves, torrential rain, and the intricate, glistening reflections of firelight across wet wooden ship planks—textures that stand out as unmatched among AI models,” said Wei Li, director of Born of the Tide and Executive Director for Big Fish & Begonia.

Kling AI is one of the world’s leading AI creative platforms, focused on next-generation tools for visual storytelling, cinematic workflows and creative production innovation. Since its launch, It has empowered over 60 million creators worldwide.
Hashtag: #KlingAI

The issuer is solely responsible for the content of this announcement.

Johnson Electric reports results for the year ended 31 March 2026

Highlights of FY25/26 Results

  • Group sales US$3,650 million – up 0.1% compared to the prior year; a decrease of 2% on a constant currency basis
  • Gross profit US$840 million or 23.0% of sales (compared to US$843 million or 23.1% of sales in the prior year)
  • Adjusted EBITA US$287 million or 7.9% of sales (compared to US$344 million or 9.4% of sales in the prior year)
  • Net profit attributable to shareholders totalled US$202 million – a decrease of 23% compared to the prior year
  • Net profit, excluding non-cash unrealized currency movements, restructuring costs, impairment of certain intangible assets, and adverse fair value movements in investments, declined by 13% to US$234 million
  • Free cash flow from operations totalled US$217 million compared to US$286 million in the prior year
  • A recommended final dividend of 44 HK cents per share (5.64 US cents)
  • As of 31 March 2026, cash reserves amounted to US$902 million (compared to US$791 million at the prior year end); and the ratio of total debt to capital was 10%

HONG KONG SAR – Media OutReach Newswire – 28 May 2026 – Johnson Electric Holdings Limited (“Johnson Electric”), a global leader in electric motors and motion subsystems, today announced its results for the twelve months ended 31 March 2026.

Group sales for the 2025/26 financial year were US$3,650 million, an increase of 0.1% compared to the prior year. Net profit attributable to shareholders decreased by 23% to US$202 million or 21.59 US cents per share on a fully diluted basis. Adjusted net profit, excluding the effects of non-cash foreign exchange rate movements, the impairment of intangible assets, restructuring charges, and adverse fair value movements in investments, declined by 13% to US$234 million.

Sales Performance

The Automotive Products Group (“APG”) achieved sales of US$3,054 million, which amounted to 84% of total Group sales. Excluding currency effects, APG’s sales decreased by 3%.

Global automotive industry production volumes increased slightly over the prior year, but growth remains lacklustre in most markets due to affordability concerns and the challenges faced by OEMs and suppliers in adjusting to geopolitical uncertainty, tariff pressures, and the shifting economics of battery electric vehicles that continue to be shaped by the level of government subsidies available to consumers.

APG’s sales are divided broadly equally across the three major geographic regions of demand, but performance over the past year reflected distinct variations in local market conditions, as well as APG’s own mix of OEM customers and the timing of new program launches.

In Asia, the division’s sales declined by 7% on a constant currency basis primarily due to the ongoing erosion in market share held by Sino-foreign joint venture OEM customers in China. APG has continued to win significant new business awards from Chinese domestic OEMs and their suppliers, which now account for the majority of its sales in China. However, the division’s historically large share among joint venture customers has acted as a drag on its recent sales performance that is taking time to reverse. The domestic passenger vehicle market in China itself experienced a sharp slowdown in sales in the first quarter of 2026 due to the phasing out of trade-in subsidies designed to encourage the purchase of electric vehicles.

APG’s sales to the Americas increased by 1% on a constant currency basis in a market that saw total light vehicle production volumes broadly flat. The predominant factor constraining new car sales in North America is cost of living concerns, with many low to middle income car buyers struggling to afford new vehicles that, on average, have increased in price by over 30% since 2020.

In Europe, APG’s sales decreased by 2% on a constant currency basis. The European auto market continues to experience sluggish consumer demand at the same time that OEMs are hampered by excess production capacity and the impact of shifting emissions regulations on their product model line-ups.

APG’s strategy in the context of the varied and unpredictable operating environment for component suppliers is, firstly, to focus on bringing to market innovative motion technologies that enable electrification, reduce emissions, and enhance passenger safety and comfort. Secondly, APG aims to offer its diverse base of customers an unrivalled total cost and value proposition that combines speed, scale, and reliability of production with an adaptable global operating footprint.

The Industry Products Group (“IPG”) achieved sales of US$596 million – an increase of 2% compared to the prior year on a constant currency basis. After three successive years of declining sales, this marks an important return to growth for the division. In more commoditized product application segments, new business development has been redirected towards the rapidly growing base of Chinese manufacturers who are capturing an increasing share of the global market for consumer and commercial hardware goods – particularly for low-priced, entry-level products. In parallel, IPG is focused on supplying motion subsystem solutions to more specialized, higher-growth segments, including humanoid robotics, warehouse automation, medical devices, semiconductor manufacturing equipment, and liquid cooling applications.

Gross Margins and Operating Profitability

The Group’s gross profit of US$840 million, or 23.0% of sales, was essentially flat compared to the prior financial year. Slight increases in production staff costs, depreciation, and raw materials were offset by savings in other production overheads and direct labour.

Reported earnings before interest, tax and amortization (“EBITA”) amounted to US$258 million, a decrease of 22% compared to US$331 million achieved in the prior year. The decline was due to a combination of factors, including higher selling and administrative staff costs and other provisions, an impairment of intangible assets arising from a past acquisition, and reduced other income due to an adverse net change in the fair value of certain investments.

Net Profit and Financial Condition

Net profit attributable to shareholders decreased by 23% to US$202 million or 21.59 US cents per share on a fully diluted basis. Adjusted net profit, excluding the effects of non-cash foreign exchange rate movements, the impairment of intangible assets, restructuring charges, and adverse fair value movements in investments, amounted to US$234 million compared to US$268 million in the prior year.

The Group’s overall financial condition remains robust with a total debt to capital ratio of 10%, an interest coverage ratio of 22 times, and year-end cash reserves of US$902 million.

Dividends

The Board considers it appropriate to recommend maintaining the final dividend of 44 HK cents (5.64 US cents) per share, which together with the interim dividend of 17 HK cents per share, represents a total dividend of 61 HK cents (7.82 US cents) per share.

Chairman’s Comments on the Annual Results and Outlook

Commenting on the annual results for the financial year 2025/26, Dr. Patrick Wang, Chairman and Chief Executive, said, “Operating conditions for global manufacturing businesses during the financial year 2025/26 remained challenging, with end-market demand in most regions subdued and geopolitical events and uncertainties placing upward pressure on input costs.”

Dr. Patrick Wang further commented: “In the face of these headwinds, Johnson Electric maintained its long-standing resilience with sales and gross profit margins both holding up comparatively well. The bottom-line result, however, was negatively impacted by the effects of higher overhead expenses on a flat sales base, adverse net changes in the fair value of investments, and a non-cash intangible assets impairment charge.”

Concerning the near-term financial outlook, Dr. Patrick Wang said: “The global economy demonstrated resilience over the past year, despite the protracted conflict between Russia and Ukraine and the geopolitical shock of tariffs being imposed on US imports of goods from almost all countries. Looking ahead, the unstable and unpredictable conditions for trade and global manufacturing have been made even more precarious by the outbreak of war in the Middle East.”

“Johnson Electric has a long-standing track record in successfully navigating volatile global markets. In the near term, with geopolitical and macro-economic dynamics impossible to forecast with precision, management remains focused on cost control, managing the effects of inflation, and maintaining a prudent financial risk profile.”

“In parallel, however, we are also committed to invest in adapting and scaling our business model to meet strong underlying demand for our motion subsystem solutions in several high-growth end-markets and new product applications. Included among these are: thermal management systems for electric and hybrid vehicles that depend on a combination of water pumps, valves and actuators to support optimal vehicle cabin temperature, extend electric vehicle driving range, and contribute to longer battery life; solid oxide fuel cell power generation systems that are becoming established as an important source of low-emission, on-site electricity supply to AI data centres; and AI-enabled humanoid robots, which are widely viewed as one of the most significant industrial and commercial opportunities over the next ten to twenty years.”

Forward Looking Statements

This news release contains certain forward looking statements with respect to the financial condition, results of operations and business of Johnson Electric and certain plans and objectives of the management of Johnson Electric.

Words such as “outlook”, “expects”, “anticipates”, “intends”, “plans”, “believe”, “estimates”, “projects”, variations of such words and similar expressions are intended to identify such forward looking statements. Such forward looking statements involve known and unknown risk, uncertainties and other factors which may cause the actual results or performance of Johnson Electric to be materially different from any future results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding Johnson Electric’s present and future business strategies and the political and economic environment in which Johnson Electric will operate in the future.

Note to Editors and Securities Analysts: The full text of the Annual Results announcement, includingfinancial statements, is available through the Investors section of company’s website at www.johnsonelectric.com
Hashtag: #JohnsonElectric

The issuer is solely responsible for the content of this announcement.

About Johnson Electric Group

At Johnson Electric, our vision is to be the world’s definitive provider of innovation and reliable motion systems.

We are a global leader in electric motors, actuators, motion subsystems and related electro-mechanical components, serving a broad range of industries including Automotive, Liquid Cooling, Robotic Joints, Smart Metering, Business Equipment, Ventilation, Home Automation, Large Appliances, Power Tools, Medical Devices and Lawn & Garden Equipment. The Group is headquartered in Hong Kong and employes over 30,000 individuals in more than 20 countries worldwide. We are listed on The Stock Exchange of Hong Kong Limited ( Stock no. 179). For further information, please visit: .

REJUVANT OUTPERFORMS ALL TESTED SUPPLEMENTS, INCLUDING STANDARD AKG AND NAD+ IN LANDMARK AGING CELL STUDY

FERNANDINA BEACH, Fla., May 28, 2026 /PRNewswire/ — Ponce De Leon Health (PDLH), a commercial stage longevity company focused on the extension of healthspan and the reduction of biologic age in humans and animals, today highlighted the publication of a landmark peer-reviewed study in the scientific journal Aging Cell. Importantly, the study was independently conducted using a large real world cohort and was not sponsored, directed, or controlled by Ponce De Leon Health.

The authors tested the association between 84 commonly used supplements, drugs and commercial compounds taken in an attempt to affect the aging process, using the same DNA methylation clock to uniformly determine the biologic age of over 4,000 initial subjects. Those results were then compared and ranked against one another. In their cross sectional analysis, only Rejuvant, a commercially available, delayed release CaAKG plus vitamins supplement, which was associated with an average 1.8 year lower age residual and was the primary study endpoint, achieved statistical significance.

In contrast, participants taking regular CaAKG/AKG showed a benefit that was eight times less effective, and was statistically insignificant. All forms of NAD+ supplements, such as NMN and NR were nine times less effective. Additionally, all of the non-Rejuvant cohorts were statistically insignificant for this endpoint, and Rejuvant remained significant in models adjusted for age, sex, smoking, health status and additional covariates.

Dr. Brian Kennedy, the Director for the Center of Healthy Longevity at the National University of Singapore, and senior author of the paper, stated “This is a unique study that compares the effects of 84 different common supplements in a larger population of generally healthy individuals actively measuring their biologic age. While a few supplements were significant for reducing biologic age, the biggest effects by far were associated with Rejuvant, whereby users were 5.74 years younger than their chronologic age. After correction for possible confounders, only Rejuvant produced a statistically significant effect. These findings reinforce my belief, supported by personally using the product for several years, that Rejuvant is effectively and meaningfully reducing biologic age”.

Dr. Nir Barzilai, President of the Academy of Geroscience and Professor of Medicine at the Albert Einstein School of Medicine, said “While many nutraceuticals have generated more enthusiasm than meaningful geroscience-based evidence, Rejuvant has at least a plausible mechanism of action and supportive preclinical data. In addition, post-marketing experience suggests a more reassuring profile for use, safety, and user satisfaction than the sweeping claims made for many other supplements. In today’s longevity marketplace, that may not be a gold standard—but it is about as close as one gets to an adult in the room.”